Medicenna to Present at Investor and Scientific Conferences in September

TORONTO and HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the Company management and scientific teams will present at the following investor and scientific conferences this month:

H.C. Wainwright 24^th Annual Global Investment Conference

An on-demand corporate presentation will be available here and on the “Investor Relations” section of Medicenna's website beginning at 7:00 am ET on September 12, 2022. Company management will also be participating in one-on-one meetings during the conference, which will take place both virtually and in-person at the Lotte New York Palace Hotel from September 12 – 14, 2022. Those interested in requesting a meeting with management should contact their H.C. Wainwright representative.  

The Promise of Interlukin-2 Therapy Conference

An overview of previously announced data from Medicenna’s IL-2 programs will be featured in an oral presentation titled, “IL-2 Superkines Engineered with Tunable Selectivity for IL2Rα, β and γ Chains Enabling Pro- and Anti-Immune Functions.” The presentation will take place at 11:30 am CEST (5:30 am ET) on September 17, 2022, during Session X: Novel IL-2s, Vectorization and Combination Therapies.

The conference is taking place at the Centre International de Conférences Sorbonne Université in Paris, France from September 14 – 17, 2022. Following the conference, slides from the oral presentation will be available on the “Events and Presentations” page of Medicenna’s website.  

Cytokines 2022: 10^th Annual Meeting of the International Cytokine & Interferon Society

Findings from Medicenna’s preclinical Superkine programs will be featured in the following two poster presentations:

1. A Next Generation Bifunctional Superkine for Immunotherapy (BiSKIT™) Encompassing the Combined Therapeutic Potency of IL-2 Super-Agonist and Anti-PD1
   
   
2. Fc-MDNA413 is a Novel Long-Acting IL-4/IL-13 Super-Antagonist that Suppresses M2a TAM Skewing and In Vivo Tumor Growth Including Synergy with an IL-2 Super-Agonist.
   

The conference is taking place both virtually and in-person at the Hilton Waikoloa Village, Big Island, Hawaii, from September 20 – 23, 2022. Both posters will be presented on 20^th September, 2022. Following the conference, copies of the posters will be available on the “Events and Presentations” page of Medicenna’s website.  

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.